Girentuximab I-124 clinical trials
How each study uses girentuximab I-124 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2005 (1)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2008 | 1 |
| 2012 | 1 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 2
Heidelberg Pharma AG (2) · Memorial Sloan Kettering Cancer Center (1) · Ludwig Institute for Cancer Research (1)
Related medicines
As reviewed, each with the page that says it.
- One of Radiopharmaceuticals source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test girentuximab I-124.
- Apr 2027Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell CarcinomaNot applicable · Memorial Sloan Kettering Cancer Center
Studies
Open first, then newest update. How each study uses girentuximab I-124 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell CarcinomaActive, not recruitingNot applicableMemorial Sloan Kettering Cancer CenterNCT01582204Written as 124IcG250
- Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.CompletedPhase 1Ludwig Institute for Cancer ResearchNCT00199888Written as 124-Iodine-cG250 (124I-cG250)
- Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-AntibodyCompletedPhase 3Heidelberg Pharma AGNCT00606632Written as 124-Iodine-cG250 (124I-cG250)
- REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CTWithdrawnPhase 3Heidelberg Pharma AGNCT01762592Written as Iodine (124I) Girentuximab
Codes
What other systems call girentuximab I-124 · ClinicalTrials.gg INT017520
- UNII (FDA) P0I0FT82VKGIRENTUXIMAB I-124One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | P0I0FT82VK | GIRENTUXIMAB I-124 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.